EGFR and central nervous system cancer: In 2021, the World Health Organization (WHO) updated its Glioma classification criteria, most notably incorporating molecular markers including CDKN2A/B homozygous deletion, TERT promoter mutation, EGFR amplification, + 7/−10 chromosome copy number changes, and others into the grading and classification of adult and pediatric Gliomas.